Skip to main content

Table 3 Patient demographics details, surgical procedure performed, treatment details, and scan duration post follow up

From: Combined amino acid PET-MRI for identifying recurrence in post-treatment gliomas: together we grow

No

Age

Location

Histology

Grade

Molecular subtype

Surgical Details immediate post op imaging not done to assess extent of resection

Chemo/Radiotherapy

Interval between Post treatment completion and PET/MRI

Duration of follow up Post PET/MRI

1

52/M

Right parietal

GBM

IV

IDH wild-type

2009: Partial resection 2009

2017: Gross Total excision of recurrence

2009: EBRT-56 Gy in 28 # with concurrent TMZ

2017: IMRT 60 Gy in 30 #, with concurrent and adjuvant TMZ completed in 2018)

12

12

2

44/M

Right posterior frontal

AA

III

IDH mutant, loss of p53

2012:Gross total excision 2017: Re-exploration and decompression 2017

2012: 56 Gy in 28 # with concurrent TMZ

2017: TMZ completed in 2018

12

13

3

42/M

Right insula

AA

III

IDH mutant

2017: Subtotal resection

2017: EBRT 55 Gy in 31 cycles

Concurrent and Adjuvant TMZ till 2018

12

13

4

71/M

Left frontal

GBM

IV

IDH wildtype

2019: Gross total excision

Defaulted treatment

 

1

5

40/F

Right Parietal

AA

III

IDH mutant

2013: Partial resection

2013: EBRT 60 Gy in 30 # with concurrent TMZ

72

3

6

32/F

Left frontal

AA

III

IDH mutant

2009: Partial resection

2013: Subtotal excision

2018: Decompression with Gross total excision

2014: EBRT 50 Gy 28 # with concurrent TMZ

2018: EBRT 30Gy in 15 cycles with concurrent TMZ

12

1

7

44/M

Right frontal

Astrocytoma

II

IDH mutant

Gross total resection 2018

Defaulted treatment

12

12

8

39/M

Right frontal

AODG

III

FISH not done

2012: Subtotal excision

2012: EBRT 60 Gy 30 # with concurrent TMZ

84

11

9

45/M

Right temporoparietal

GBM

IV

IDH wildtype

2018: Gross Total excision

2018: IMRT with concurrent and adjuvant TMZ (last 2018)

12

4

10

22/M

Right parietooccipital

GBM

IV

IDH wildtype

2013: Gross Total excision

2013: EBRT 46 Gy 25 #, 10 Gy 15 # with concurrent TMZ

72

3

11

30/M

Left temporal

AA

III

IDH mutant

2018: Gross Total excision

2019: EBRT 45 Gy 25 # booster 14.4 Gy 8 # with concurrent TMZ

24

6

12

39/M

Left inferior frontal

AA

III

IDH wildtype

2018: Gross Total excision

2018-2019 EBRT 60 Gy 30 # with concurrent TMZ

1

12

13

34/F

Right frontal

AODG

III

IDH mutant

2018: Decompression

2019: EBRT 59.4Gy in 33 # with concurrent TMZ

12

5

14

16/M

Left thalamus

Midline glioma

IV

H3K27 mutant

2019: Partial excision and decompression

2019: TMZ followed by EBRT: 49.5 Gy 33 #

1

9

15

29/M

Right parietal

GBM

IV

IDH wildtype

2017: Decompression

2018: Not operable

2017: EBRT 60Gy in 30 # with concurrent TMZ

2018: TMZ

18

4

16

42/F

Left frontal

AA

III

IDH mutant

2016: Gross Total excision

2016: EBRT 60 Gy 30 # with concurrent TMZ

32

3

17

51/F

Left temporal

GBM

IV

IDH wildtype

2018: Gross Total excision

2018: 2016: EBRT 60 Gy 30 # with concurrent TMZ

2

10

18

29/F

Right parietal

GBM

IV

NOS(R132H negative)

2018: Gross Total excision

2019: IMRT 59.5 Gy 33 # with concurrent TMZ

1

7

19

40/M

Left temporal

GBM

IV

NOS(R132H negative)

2018: Near total excision

2019: Gross Total excision

2018: EBRT 54.4 Gy 33 # with concurrent TMZ

13

1

20

8/F

Right frontoparietal

High grade glioma

IV

IDH wildtype

2018: Gross Total resection

2018: IMRT RT 60Gy 33 # with concurrent TMZ

20

3

21

16/M

Right Frontal

Spindle cell Sarcoma

III

NA

2016: Near total excision

2018: EBRT 54.4 Gy 33 # with concurrent TMZ

  

22

29/F

Left frontal

AA

III

IDH wildtype

2017: Gross Total excision

2017: EBRT 60Gy 33 # with concurrent TMZ

24

10

23

44/M

Right frontal

AA

III

IDH mutant

2016: Gross total excision

2016: EBRT 60Gy 30 # with concurrent TMZ

33

9

24

45/F

Right temporoparietal

AODG; Final-Anaplastic ependymoma

III

IDH wildtype, L1CAM positive

2017: Gross total excision

2017: EBRT 60Gy 30 # with concurrent TMZ

24

1

25

32/F

Left temporoparietal

AODG

III

IDH mutant

2018: Near Total excision

2018 EBRT 60Gy 30 # with concurrent TMZ

12

3

26

35/F

Left parietal

AODG

III

R132H negative

2017: Decompression with near total excision

2018: EBRT 60Gy 30 # with concurrent and adjuvant TMZ

8

7

27

31/M

Left frontoinsular

AODG

III

IDH mutant

2019: Subtotal excision n

2019: EBRT 60Gy 30 # with concurrent and adjuvant TMZ (on going)

1

3

28

44/M

Right frontal and corpus callosum

ODG

II

NA

2014: Subtotal excision

2014: Incomplete treatment EBRT 10 #

2019: 6 cycles of TMZ

60

8

29

48/M

Right parietooccipital

AA

III

IDH mutant

2017: Near Total excision

2017: EBRT 60Gy 30 # with concurrent TMZ

29

7

30

28/M

Left temporal

GBM

IV

IDH wildtype

2015: Subtotal excision

2016: EBRT 60Gy 30 # with concurrent TMZ

59

1

31

59/M

Right temporal

GBM

IV

IDH wildtype

2019: Gross total excision

2020: Recurrence- Gross total resection

2019: EBRT 60Gy 30 # with concurrent TMZ

2020: Adjuvant TMZ

4

1

32

47/M

Left temporoparietal

AODG

III

IDH mutant

2015: Gross total excision

2016: EBRT 60Gy 30 # with concurrent TMZ

48

6

33

30/M

Corpus callosum

GBM

IV

IDH wildtype

2016: Partial resection

2016:EBRT 43 Gy in 23 # with concurrent TMZ

40

1

34

31/M

Bifrontal

AODG

III

IDH mutant

2018: Near total excision

2019: EBRT 60 Gy in 30 #, with concurrent TMZ

11

5

35

35/M

Right parietal

ODG

II

IDH mutant

2016: Gross Total excision

2016: EBRT 55.8 Gy in 30# no chemotherapy

40

4

36

40/M

Right frontal

AA

III

IDH mutant

2019: Gross Total excision

2019: EBRT 60 Gy in 30 #, with concurrent TMZ

7

7

37

43/F

Right parietal

AODG

III

NA

2013: Subtotal excision

2013; EBRT 60 Gy in 30 #, NO chemotherapy received, lost to follow-up for 6 years

78

5

38

68/M

Left frontal

GBM

IV

IDH wildtype

2019: Gross total excision

2020: EBRT 60 Gy in 30 #, with concurrent TMZ

1

4

39

32/F

Right frontal

AODG

III

IDHR132H neg

2018: Gross Total excision

2018: EBRT 60 Gy in 33 cycles#, with concurrent TMZ

15

4

40

51/F

Right frontal

AODG

III

IDH mutant

2018: Gross Total excision

2018: EBRT 60 Gy in 33 cycles#, with concurrent TMZ

22

4

41

36/M

Right frontal

AA

III

IDH mutant

2018: Gross Total excision

2018: EBRT 60 Gy in 30 cycles#, with concurrent TMZ

17

13

42

57/M

Right frontal

AODG

III

IDH mutant

2018: Gross Total excision

2018: EBRT 60 Gy in 30 cycles#, with concurrent TMZ

10

13

43

36/F

Left frontoparietal

GBM

IV

IDH mutant

2009: Gross Total excision

2016: Recurrence- re-exploration subtotal excision

2009: EBRT60 Gy in 30 cycles#, with concurrent TMZ

2016: EBRT alone with no chemotherapy

2017: Bevacizumab

24

13

44

34/M

Right temporoparietal

AODG

III

IDH mutant

2018: Near total excision

2019: Re exploration subtotal excision

2018: 60 Gy in 30 cycles#, with concurrent TMZ

2

14

45

69/F

Right temporal

GBM

IV

IDH wildtype

2019: Gross total excision

2019: 60 Gy in 30 cycles#, with concurrent TMZ

6

1

46

51/M

Left temporal

AODG

III

IDH wildtype

2019: Gross total excision

2019: 60 Gy in 30 cycles#, with concurrent TMZ

3

13

47

50/M

Left parietal

GBM

IV

IDH wildtype

2018: Gross total excision

2018: EBRT RT 60 Gy in 30 cycles#, lost to follow-up

12

12

48

43/F

Right parietal

AODG

III

NA

2017: Gross total excision

2018: EBRT RT 60 Gy in 30 cycles#, lost to follow-up

78

7

  1. GBM glioblastoma multiforme, AA anaplastic astrocytoma, AODG anaplastic oligodendro glioma, ODG oligodendroglioma. Size of the tumour could not be measured because all 11C PET MRI were performed post chemoRT; hence, anatomical distortion on MRI images to give relevant sizes (MRI Volumetric analysis not done)